Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2000

View Archived Issues

Immunosuppressive agents and their use in airways diseases

SB Biologicals develops vaccine and therapeutic compositions for meningococcal disease

5-HT receptor ligands in development at Cerebrus for obesity and other disorders

RP105 antagonists and their use described by SmithKline Beecham

Synsorb Biotech commences phase III clinical trials with Synsorb Cd for CDAD

Gemini establishes drug target discovery collaboration with CuraGen

Canadian government invests heavily in BioChem Pharma's vaccine development program

Medarex and Coulter form human antibody collaboration agreement

Sildenafil helps improve conception in an unexpected way

British Biotech designs more MMP-inhibitory hydroxamic acid derivatives

Alosetron now available in U.S.; first drug to address multiple symptoms of IBS in women

Inhibitors of several signal transduction pathways under study at AstraZeneca for cancer, etc.

Pfizer research team focuses on design of new antitumor agents

More news from ACS: Oridigm selects two lead apoptosis-inducing polyamine analogues

NMI-678-11 and NMI-837-11: new nitrosylated moxisylyte derivatives for erectile dysfunction

Potent second-generation HIV protease inhibitors designed by Vertex & Glaxo Wellcome

AHP and Elan form alliance to develop Alzheimer's vaccine

Cardioprotective effects of KB-R9032 involve adenosine receptor stimulation

Commercial rights to Viadur licensed to Bayer for advanced prostate cancer

Triangle and Dynavax to develop immunotherapeutics for HIV and hepatitis

PNU-145185 as lead herpesvirus DNA polymerase inhibitor with broad-spectrum activity

SafeScience's phase II pancreatic cancer trial commences at Beth Israel Deaconess

Pyridobenzodiazepine class of antidiuretics with potent oral activity presented at ACS meeting

Generex initiates clinical trials of oral insulin in Italy

Novel antitumor agent SJG-136 selected for further preclinical development by NCI

Onyx and Parke-Davis present cell cycle and biochemical effects of PD-0183812

Favorable PK, lack of PK interaction with ciclosporin seen for RAD-001 in lung transplant patients

Merck reports identification of selective, orally active beta3-AR agonist devoid of cardiac effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Molecular signatures show subtypes in neurodegenerative diseases
BioWorld Science
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...